Log In Sign up
The largest database of trusted experimental protocols

Anti hla a2 fitc antibody

Manufactured by BioLegend
Visit Supplier

The Anti-HLA-A2 FITC antibody is a laboratory reagent used for the detection and identification of HLA-A2 antigen expression on cells. It is conjugated with the fluorescent dye FITC, allowing for detection and quantification of HLA-A2 positive cells through flow cytometry or other fluorescence-based techniques.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

FITC anti-human HLA-A2 antibody Anti-HLA-A2 antibody HLA-A2-FITC

2 protocols using anti hla a2 fitc antibody

1

Quantifying HLA-A2 pMHC Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols
Streptavidin coated nanovials were functionalized with biotinylated HLA-A*02:01 restricted NY-ESO-1 pMHC by incubating at various concentrations (0, 20, 40, 80, 90, 100 μg/mL) and washed three times as described in Nanovial Functionalization section. Nanovials were reconstituted at a ten-fold dilution in Washing Buffer containing 2 μL of 100 μg/mL anti-HLA-A2 FITC antibody (Biolegend, 343304) and incubated for 30 minutes at 37°C. After washing three times with Washing Buffer, mean fluorescence intensity was measured by flow cytometry.
Koo D., Mao Z., Dimatteo R., Tsubamoto N., Noguchi M., McLaughlin J., Tran W., Lee S., Cheng D., de Rutte J., Sojo G.B., Witte O.N, & Di Carlo D. (2023). Defining T cell receptor repertoires using nanovial-based affinity and functional screening. bioRxiv.
+ Open protocol
+ Expand
2

Quantifying Cell Surface HLA-A2 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were incubated with anti-HLA-A2-FITC antibody (BioLegend, cat. 343304) or anti-IgG2b-FITC isotype control antibody (BioLegend, cat. 401206) diluted at 1:50 in PBS for 30 min at 4°C. Cells were washed and resuspended in 50 μl of FACS buffer (PBS + 0.5% BSA + 4 Mm EDTA). Data was acquired using BD Accuri C6 platform (BD Biosciences) and represented as relative abundance in mean fluorescence intensity (MFI) relative to isotype/unstained ratio.
Harper J., Adams K.J., Bossi G., Wright D.E., Stacey A.R., Bedke N., Martinez-Hague R., Blat D., Humbert L., Buchanan H., Le Provost G.S., Donnellan Z., Carreira R.J., Paston S.J., Weigand L.U., Canestraro M., Sanderson J.P., Botta Gordon-Smith S., Lowe K.L., Rygiel K.A., Powlesland A.S., Vuidepot A., Hassan N.J., Cameron B.J., Jakobsen B.K, & Dukes J. (2018). An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLoS ONE, 13(10), e0205491.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!